- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01531725
MULTIcentric BElgium/NEtherlands PRO-Kinetic Safety and Efficacy Study (MULTIBENE)
6 Months Evaluation of the BIOTRONIK PRO-Kinetic Coronary Stent System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The PRO-Kinetic study is a multi-center, prospective, consecutive non-randomized study enrolling 200 patients with single de novo lesions in native coronary arteries meeting the entry criteria. Those who provide informed consent will be enrolled to receive the PRO-Kinetic stent. Telephone follow-up will be performed at 1 month for all enrolled patients. After 6 months 100 patients will have an angiographic follow-up and 100 patients will be checked by telephone again. Additionally, a clinical telephone follow-up will be performed in all patients after 12 months.
This study is designed to yield data on the clinical safety and efficacy of the PRO-Kinetic stent in the coronary artery application. The Target Vessel Failure Rate after 6 months shall be below 18 % (max. 35 Serious Adverse Events and Expedited Events) to show a safety/performance profile that could be considered in the range of the currently available bare metal stent systems
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must be at least 18 years old.
- Eligible for percutaneous coronary intervention (PCI).
- Documented stable (Canadian Cardiovascular Society Classification [CCS] 1, 2, 3, or 4) or unstable (Braunwald type I, II, III and A, B or C) angina pectoris, or documented silent ischemia.
- Left ventricular ejection fraction (LVEF) > 30% documented within the last 6 weeks.
- Acceptable candidate for coronary artery bypass graft surgery (CABG).
- Patient understands the study requirements and the treatment procedures and provides written Informed Consent on a form that has been approved the by local Institutional Review Board before any specific test of the study or procedure is performed.
- Willing to comply with all the specified follow-up evaluations.
- Single target vessels to be treated.
- Single target lesion to be treated.
- Target lesion must be completely coverable by one study stent.
- Total target lesion length <20 mm based on a visual estimate.
- RVD of ≥ 2.0 mm to ≤ 5.0 mm based on a visual estimate.
- Target lesion diameter stenosis ≥ 50% and < 100% based on a visual estimate.
- Target lesion has not undergone prior revascularization up to now.
- Target vessel has not undergone prior revascularization within the preceding 6 months.
- Patient has no child bearing potential, is not pregnant, or intends to become pregnant during the study.
Exclusion Criteria:
- Planned treatment with any other PCI device in target vessel except the pre-dilatation balloon.
- MI within 72 hours prior to the index procedure and/or creatine kinase (CK) > 2 times the local laboratory upper limits of normal, measured on the day of the index procedure, associated with elevated MB.
- The patient is in cardiogenic shock.
- Cerebrovascular Accident (CVA) within the past 6 months.
- Acute or chronic renal dysfunction (creatinine > 2.0 mg/dl or > 150 µmol/L).
- Contraindication to ASA or to clopidogrel.
- Known Thrombocytopenia (platelet count 100, 000/mm3).
- Active gastrointestinal (GI) bleeding within the past three months.
- Known allergy to stainless steel or cobalt chromium.
- Any prior true anaphylactic reaction to contrast agents.
- Patient is currently taking colchicine.
- Life expectancy of less than 24 months due to other medical conditions.
- Co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.
- Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
- Left main coronary artery disease (stenosis > 50%), whether protected or unprotected.
- Target lesion site is ostial (within 3.0 mm of vessel origin).
- Target lesion and/or target vessel proximal to the target lesion is severely calcified by visual estimation.
- Target lesion involves a bifurcation that requires intervention (usually, side branch >2 mm in diameter).
- Target lesion is totally occluded (100% stenosis usually associated with TIMI flow ≤1).
- Angiographic presence of probable or definite thrombus.
- Target vessel will be pre-treated with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter prior to stent placement.
- Prior coronary intervention using brachytherapy to any segment of the target vessel.
- Angiographic restenosis of any segment of the target vessel that has undergone prior percutaneous coronary intervention.
- Angiographic evidence of atherosclerotic disease with > 50% diameter stenosis (by visual estimate) proximal or distal to the target lesion
- Prior surgical revascularization of the target vessel with a documented patent graft (either a saphenous vein or an arterial conduit).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BMS implantation
Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent).
Since it is a single arm study design, no patients are enrolled to a control arm.
|
Percutaneous coronary intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target Vessel Failure (TVF)
Time Frame: at 180 days post procedure
|
Target vessel failure is defined as composite of revascularization, recurrent myocardial infarction, or cardiac death.
|
at 180 days post procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Adverse Cardiac Events (MACE)
Time Frame: at 180 days post procedure
|
MACE is defined as a composite of death, myocardial infarction, target lesion revascularization and coronary artery bypass grafting.
|
at 180 days post procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Vermeersch, MD, PhD, ZNA Middelheim, Department Interventional Cardiology
- Principal Investigator: Maarten J. Suttorp, MD, PhD, St. Antonius Hospital Nieuwegein
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C0601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Percutaneous coronary intervention
-
Mid and South Essex NHS Foundation TrustImperial College LondonRecruitingStable Angina | Chronic Total Occlusion of Coronary ArteryUnited Kingdom
-
University Hospital, SaarlandCompletedAcute Myocardial InfarctionGermany
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCoronary Artery DiseaseChina
-
University Hospital of PatrasCompletedCoronary Artery Bypass SurgeryGreece
-
Yonsei UniversityUnknownCoronary Artery Disease | Stable Angina | Unstable AnginaKorea, Republic of
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Herlev and Gentofte HospitalUnknownCoronary Heart Disease | Ischemic Heart Disease | Stable AnginaDenmark
-
RobocathCompletedCoronary Artery Disease | Percutaneous Coronary InterventionFrance, Belgium, Luxembourg, Netherlands
-
University College, LondonNational Institute for Cardiovascular Outcomes Research; British Cardiovascular... and other collaboratorsCompletedPercutaneous Coronary InterventionUnited Kingdom
-
Niels Ramsing HolmJohnson & JohnsonUnknown